Placebo (for ATG)

DRUG2 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Diabetes Mellitus, Type 1

Phase 2

ATG-GCSF in New Onset Type 1 Diabetes

CompletedNCT02215200

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Diabetes Mellitus, Type 1

Start: 2014-12-31End: 2018-08-31Updated: 2020-03-02

STOP-T1D Low-Dose (ATG)

TerminatedNCT04291703

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Diabetes Mellitus, Type 1

Start: 2023-11-01End: 2024-12-17Updated: 2025-09-25

Related Papers

Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.

2024-12-204 citations

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

JCI Insight2023-07-1130 citations

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

2016-04-0668 citations